IDEXX Laboratories (NASDAQ:IDXX) Insider Jonathan Jay Mazelsky Sells 25,140 Shares of Company Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Jonathan Mazelsky sold 25,140 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the transaction, the insider directly owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. This trade represents a 23.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

IDEXX Laboratories Stock Down 4.0%

IDEXX Laboratories stock traded down $27.84 during mid-day trading on Thursday, reaching $670.71. The company’s stock had a trading volume of 873,031 shares, compared to its average volume of 583,252. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.87 and a current ratio of 1.19. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The business’s 50 day simple moving average is $541.78 and its 200 day simple moving average is $573.62. The company has a market capitalization of $52.85 billion, a price-to-earnings ratio of 45.23 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.22 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 15.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IDXX. Barclays lowered their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research report on Friday, October 30th. They issued a “buy” rating for the company. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Leerink Partners dropped their target price on shares of IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $719.55.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in IDEXX Laboratories by 4.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after buying an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in IDEXX Laboratories by 52.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after buying an additional 288,471 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of IDEXX Laboratories by 4.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after buying an additional 23,582 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after buying an additional 197,808 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.